Please assess the completion status of the following clinical trial:

Trial Title: Study of Genexol-PM in Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine and Platinum

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed TCC of the urothelial tract (bladder, renal pelvis, or ureter)~2. Prior exposure to gemcitabine-platinum regimen as either adjuvant or palliative chemotherapy.~3. Unidimensionally measurable disease outside prior radiotherapy ports~4. Age 18 years or older~5. ECOG performance status of 0\~2~6. Life expectancy of at least 3 months~7. Adequate BM function (ANC \>1,500/mm3 \& Platelet \>100,000/mm3)~8. Adequate hepatic function (Bilirubin no greater than 2 times upper limit of normal (ULN) \& AST or ALT no greater than 2.5 times ULN), and renal function (creatinine \<1.5 X times ULN)~9. No pre-existing clinically significant grade 2 or greater neuropathy~Exclusion Criteria:~1. Pregnant or lactating patients~2. Presence or history of CNS metastasis~3. Patients with prior RT to the axial skeleton within 4 weeks of chemotherapy start to greater than 25% of bone marrow~4. Any preexisting medical condition of sufficient severity to prevent full compliance with the study, including active infection, active cardiac symptoms

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Genexol PM (Type: EXPERIMENTAL): Genexol PM intravenous infusion every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).